中国批准VYLOYTM用于高级胃癌,针对中国患者的普通生物标记。 China approves VYLOY™ for advanced gastric cancer, targeting a common biomarker in Chinese patients.

中国已经批准VYLOYTM(Zolbetuximab)治疗先进的胃胃癌或胃道切入式癌症,针对的对象是Claudin 18.2, 35%的中国受影响病人中都有生物标志。 China has approved VYLOY™ (zolbetuximab) for treating advanced gastric or gastroesophageal junction cancer, targeting claudin 18.2, a biomarker present in 35% of affected Chinese patients. 这一批准是在成功进行第三阶段试验后批准的,试验显示存活率有所改善。 This approval follows successful Phase 3 trials showing improved survival rates. 中国的胃癌每年导致260,000多人死亡,五年内存活率低,为9.1%。 Gastric cancer leads to over 260,000 deaths annually in China and has a low five-year survival rate of 9.1%.